Quote | Inhibikase Therapeutics Inc. (NASDAQ:IKT)
Last: | $1.16 |
---|---|
Change Percent: | -4.3% |
Open: | $1.2 |
Close: | $1.16 |
High: | $1.4 |
Low: | $1.14 |
Volume: | 40,441 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Inhibikase Therapeutics Inc. (NASDAQ:IKT)
2024-06-18 17:44:20 ET More on Inhibikase Therapeutics Inhibikase Therapeutics prices its direct offering, warrant inducement Seeking Alpha’s Quant Rating on Inhibikase Therapeutics Historical earnings data for Inhibikase Therapeutics Read the full a...
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
Message Board Posts | Inhibikase Therapeutics Inc. (NASDAQ:IKT)
Subject | By | Source | When |
---|---|---|---|
short squeeze all day | jedijazz | investorshub | 04/27/2023 11:17:06 PM |
Price trading | conix | investorshub | 04/27/2023 9:40:57 PM |
$IKT Long and strong lets hope im right | TrendTrade2016 | investorshub | 04/27/2023 2:06:36 PM |
$IKT Price trading | estreet7883 | investorshub | 04/27/2023 3:50:09 AM |
$IKT Time for a bounce? | conix | investorshub | 04/27/2023 2:47:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Inhibikase Therapeutics Inc. Company Name:
IKT Stock Symbol:
NASDAQ Market:
Inhibikase Therapeutics Inc. Website:
BOSTON and ATLANTA, June 17, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinso...
- Company positioning multiple assets for late-stage development across its therapeutic pipeline – BOSTON and ATLANTA, June 05, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kin...
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease, Parkinson...